{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:52:59Z","timestamp":1785901979395,"version":"3.56.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI22C0537"],"award-info":[{"award-number":["HI22C0537"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["NRF - 2020R1C1C1008346"],"award-info":[{"award-number":["NRF - 2020R1C1C1008346"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.trsl.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T02:27:07Z","timestamp":1676687227000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model"],"prefix":"10.1016","volume":"258","author":[{"given":"Sheng","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hun","family":"Eum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jeong","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Woo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Kyung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Woo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-5717","authenticated-orcid":false,"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2023.02.005_bib0001","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2023.02.005_bib0002","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0003","doi-asserted-by":"crossref","first-page":"208","DOI":"10.23876\/j.krcp.20.264","article-title":"Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis","volume":"40","author":"Chung","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.trsl.2023.02.005_bib0004","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2215\/CJN.09480819","article-title":"The changing landscape of Fabry disease","volume":"15","author":"Svarstad","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.23876\/j.krcp.21.056","article-title":"Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease","volume":"40","author":"Kim","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.trsl.2023.02.005_bib0006","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","article-title":"Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.trsl.2023.02.005_bib0007","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2023.02.005_bib0008","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.trsl.2023.02.005_bib0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0010","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(15)60206-9","article-title":"Eliglustat for Gaucher's disease: trippingly on the tongue","volume":"385","author":"Hughes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2023.02.005_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.trsl.2023.02.005_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","article-title":"an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Guerard","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.trsl.2023.02.005_bib0013","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1002\/anie.200902620","article-title":"Glycosphingolipids\u2013nature, function, and pharmacological modulation","volume":"48","author":"Wennekes","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.trsl.2023.02.005_bib0014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1537-2995.2007.01552.x","article-title":"Expression of a novel missense mutation found in the A4GALT gene of Amish individuals with the p phenotype","volume":"48","author":"Hellberg","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.trsl.2023.02.005_bib0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-3148.2010.01055.x","article-title":"Functional characterisation of a complex mutation in the alpha(1,4)galactosyltransferase gene in Taiwanese individuals with p phenotype","volume":"21","author":"Wang","year":"2011","journal-title":"Transfus Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0016","first-page":"130","article-title":"Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice","volume":"48","author":"Lee","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.trsl.2023.02.005_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41536-021-00198-0","article-title":"SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease","volume":"7","author":"Park","year":"2022","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0018","first-page":"e54650","article-title":"Induced pluripotent stem cell generation from blood cells using sendai virus and centrifugation","volume":"118","author":"Rim","year":"2016","journal-title":"J Vis Exp"},{"key":"10.1016\/j.trsl.2023.02.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2021.102214","article-title":"Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation","volume":"51","author":"Cui","year":"2021","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.trsl.2023.02.005_bib0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.23876\/j.krcp.20.252","article-title":"Modeling of endothelial cell dysfunction using human induced pluripotent stem cells derived from patients with end-stage renal disease","volume":"40","author":"Kim","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.trsl.2023.02.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.102110","article-title":"Generation of a human induced pluripotent stem cell line (CMCi002-A) from a patient with Gitelman's syndrome","volume":"49","author":"Lim","year":"2020","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.trsl.2023.02.005_bib0022","first-page":"153","article-title":"Modeling kidney disease with iPS cells","volume":"10","author":"Freedman","year":"2015","journal-title":"Biomark Insights"},{"key":"10.1016\/j.trsl.2023.02.005_bib0023","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1038\/ncomms9715","article-title":"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids","volume":"6","author":"Freedman","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2023.02.005_bib0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.34067\/KID.0000422019","article-title":"Profiling APOL1 nephropathy risk variants in genome-edited kidney organoids with single-cell transcriptomics","volume":"1","author":"Liu","year":"2020","journal-title":"Kidney360."},{"key":"10.1016\/j.trsl.2023.02.005_bib0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nmat4994","article-title":"Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease","volume":"16","author":"Cruz","year":"2017","journal-title":"Nat Mater"},{"key":"10.1016\/j.trsl.2023.02.005_bib0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.mcb.2019.05.003","article-title":"Differentiation of human kidney organoids from pluripotent stem cells","volume":"153","author":"Cruz","year":"2019","journal-title":"Methods Cell Biol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0027","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/cclm-2016-0340","article-title":"Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS\/MS","volume":"55","author":"Polo","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0028","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ymeth.2006.05.004","article-title":"Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry","volume":"39","author":"Bielawski","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.trsl.2023.02.005_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.trsl.2023.02.005_bib0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/cells8040327","article-title":"Generation of GLA-knockout human embryonic stem cell lines to model autophagic dysfunction and exosome secretion in fabry disease-associated hypertrophic cardiomyopathy","volume":"8","author":"Song","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.trsl.2023.02.005_bib0031","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","article-title":"BEDTools: a flexible suite of utilities for comparing genomic features","volume":"26","author":"Quinlan","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.trsl.2023.02.005_bib0032","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0033","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/3327","article-title":"Real-time quantitative RT-PCR after laser-assisted cell picking","volume":"4","author":"Fink","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0034","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2023.02.005_bib0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0036","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2023.02.005_bib0037","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2023.02.005_bib0038","first-page":"11","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.trsl.2023.02.005_bib0039","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","article-title":"CRISPR Gene Editing in the Kidney","volume":"71","author":"Cruz","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2023.02.005_bib0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41581-018-0047-x","article-title":"Precision gene editing technology and applications in nephrology","volume":"14","author":"WareJoncas","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121429","article-title":"Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR\/Cas9-engineered patient iPSCs","volume":"283","author":"Son","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.trsl.2023.02.005_bib0042","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5966\/sctm.2015-0157erratum","article-title":"Naive Induced pluripotent stem cells generated from beta-thalassemia fibroblasts allow efficient gene correction with CRISPR\/Cas9","volume":"5","author":"Yang","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0043","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.omtn.2021.08.015","article-title":"CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs","volume":"26","author":"Sladen","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.trsl.2023.02.005_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102633","article-title":"Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells","volume":"52","author":"Do","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.trsl.2023.02.005_bib0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2011.06.007","article-title":"Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide","volume":"104","author":"De Francesco","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.trsl.2023.02.005_bib0046","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.trsl.2023.02.005_bib0047","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","article-title":"Human kidney organoids reveal the role of glutathione in Fabry disease","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0048","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3390\/ijms22052381","article-title":"Reversal of the inflammatory responses in fabry patient iPSC-derived cardiovascular endothelial cells by CRISPR\/Cas9-corrected Mutation","volume":"22","author":"Song","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2023.02.005_bib0049","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1681\/ASN.2006090983","article-title":"Bmp in podocytes is essential for normal glomerular capillary formation","volume":"19","author":"Ueda","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.matbio.2015.01.013","article-title":"ADAMTS proteases and cancer","volume":"44-46","author":"Cal","year":"2015","journal-title":"Matrix Biol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0051","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1074-7613(01)00254-0","article-title":"Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity","volume":"15","author":"Murga","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2023.02.005_bib0052","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1111\/jcmm.14973","article-title":"C-X-C motif chemokine receptor 4 aggravates renal fibrosis through activating JAK\/STAT\/GSK3beta\/beta-catenin pathway","volume":"24","author":"Liu","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.trsl.2023.02.005_bib0053","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/cmi.2016.47","article-title":"Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus","volume":"14","author":"Zhao","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0054","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2369-9-10","article-title":"Mutant polycystin-2 induces proliferation in primary rat tubular epithelial cells in a STAT-1\/p21-independent fashion accompanied instead by alterations in expression of p57KIP2 and Cdk2","volume":"9","author":"Felekkis","year":"2008","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trsl.2023.02.005_bib0055","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.4161\/cc.22375","article-title":"CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD","volume":"11","author":"Bukanov","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trsl.2023.02.005_bib0056","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Hollak CE. Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.trsl.2023.02.005_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101676","article-title":"Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR\/Cas9","volume":"42","author":"Kim","year":"2020","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.trsl.2023.02.005_bib0058","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","article-title":"Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease","volume":"37","author":"Itier","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.trsl.2023.02.005_bib0059","article-title":"Reduced alpha-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype","volume":"31","author":"Elsaid","year":"2022","journal-title":"Mol Genet Metab Rep"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524423000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524423000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:46:56Z","timestamp":1761828416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524423000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":59,"alternative-id":["S1931524423000257"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2023.02.005","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}